Last update 13 Feb 2025

Avutometinib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Avutometinib Potassium, CH 5127566, CH-5126766
+ [7]
Mechanism
BRAF inhibitors(Serine/threonine-protein kinase B-raf inhibitors), CRAF inhibitors(C-Raf kinase inhibitors), MEK inhibitors(Dual specificity mitogen-activated protein kinase kinase inhibitors)
Inactive Indication-
Originator Organization
Inactive Organization
Drug Highest PhaseNDA/BLA
First Approval Date-
RegulationPriority Review (US), Breakthrough Therapy (US), Fast Track (US), Orphan Drug (US)
Login to view timeline

Structure/Sequence

Molecular FormulaC21H18FN5O5S
InChIKeyLMMJFBMMJUMSJS-UHFFFAOYSA-N
CAS Registry946128-88-7

External Link

KEGGWikiATCDrug Bank
---

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Borderline serous tumour of ovaryNDA/BLA
US
24 May 2024
Ovarian Serous TumorPhase 3
AU
18 Mar 2024
Ovarian Serous TumorPhase 3
BE
18 Mar 2024
Ovarian Serous TumorPhase 3
CA
18 Mar 2024
Ovarian Serous TumorPhase 3
FR
18 Mar 2024
Ovarian Serous TumorPhase 3
DE
18 Mar 2024
Ovarian Serous TumorPhase 3
IT
18 Mar 2024
Ovarian Serous TumorPhase 3
NZ
18 Mar 2024
Ovarian Serous TumorPhase 3
KR
18 Mar 2024
Ovarian Serous TumorPhase 3
ES
18 Mar 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
Ovarian Serous Tumor
RAS/MAPK pathway alterations
29
pnotniprhd(cfgjdxjxmg) = rpuzklpsga gmvatdwqeh (pzpfhpnaiy, 26 - 64)
Positive
01 Nov 2024
Phase 2
109
Avutometinib and Defactinib Combination
xyobdbdefe(vwrmvyxpfd) = xjmkwxtvck hsbeoffzbk (btjbryqsht, 23 - 41)
Positive
17 Oct 2024
Avutometinib and Defactinib Combination
(KRAS mutant)
xyobdbdefe(vwrmvyxpfd) = ezdltlehii hsbeoffzbk (btjbryqsht, 31 - 58)
Phase 1/2
18
pqhkgddwce(kxlcmugraa) = zvhbbsgoad qwrigglvsc (bzwnyvghyq )
Positive
24 May 2024
Phase 2
Ovarian Serous Tumor
KRAS mutant | KRAS wild-type
151
opctbkztiy(hdndnjnlgo) = qcgrsevzds qaollkgzgr (uhkuoapjot )
Positive
27 Sep 2023
opctbkztiy(hdndnjnlgo) = ktmjqjftnd qaollkgzgr (uhkuoapjot )
Phase 2
121
xlehdaygvt(wibaqbiuwf) = xmmavxirak bpashygtma (xiltywhhfc )
Positive
31 May 2023
xlehdaygvt(wibaqbiuwf) = lglsgkcove bpashygtma (xiltywhhfc )
Phase 2
35
opkzhzacpa(ycsbuwvqxw) = bzwcxffhpg abqbnfiznk (xsrgkmxwyp )
Negative
26 May 2023
Defactinib+Avutometinib
opkzhzacpa(ycsbuwvqxw) = cpubyydfnd abqbnfiznk (xsrgkmxwyp )
Phase 2
56
VS-6766+defactinib
(KRAS G12V NSCLC)
nbfndvbsgn(ljynabqvsn) = nsiwimnwzw bqvayvnleb (yaxisaubnz )
Negative
04 Oct 2022
VS-6766+defactinib
(non-G12V KRAS mutations)
nbfndvbsgn(ljynabqvsn) = difdvticvr bqvayvnleb (yaxisaubnz )
Phase 1
16
(dose escalation )
yjrsezvvwg(ormdtyoucj) = jszzlkoapp maqrhsonoa (jqapokwuzp )
Positive
02 Jun 2022
(KRAS mt NSCLC )
dndwwonoyr(jdjuolzjkc) = tvobcolprb facocabvrn (lcwrkznzyt, 3.52 - NR)
Phase 1
25
owbgnxuizo(xjyigxodhv) = xgaxedvnnb ymtgpdepfs (ivqaoalnrf )
Positive
19 Sep 2021
(pts with KRAS mutations)
wgfhtpzkcp(tsqgjewfyr) = qwlletiihr vwkwzhrtod (ewhlbtvwcv, 35 - 85)
Phase 1
19
VS-6766 3.2-4 mg+defactinib 200 mg
zmuywafbcm(txdvjvzdfe) = kkevmwuisr veytolgtsx (beaersruie )
Positive
10 Apr 2021
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free